ArticleBMC gastroenterology2025
Application of continuous renal replacement therapy (CRRT) in patients with severe acute pancreatitis: an analytical study.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Predicting the Initiation of Continuous Venovenous Hemofiltration in Acute Pancreatitis Patients: The Role of Plasma and Urinary Neutrophil Gelatinase-Associated Lipocalin.Journal of clinical medicine · 2026Article
- Comparison of the efficacy and safety of nafamostat mesylate and heparin in blood purification therapy for patients with severe acute pancreatitis: protocol for a randomized controlled trial.Frontiers in medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
purposeTo Explore the correlation between Continuous Renal Replacement Therapy (CRRT) and the prognostic outcomes of patients with Severe Acute Pancreatitis (SAP); to analyze the impact of CRRT initiation time on the final prognosis of SAP patients; to evaluate factors affecting the therapeutic effect of CRRT in SAP patients without absolute indications for CRRT, and to develop a multi-factorial predictive model for the efficacy of CRRT in treating SAP.
methodsThis retrospective cohort study analyzed clinical data from SAP patients admitted to The Affiliated LiHuili Hospital of Ningbo University (2015-2024), collecting baseline characteristics (demographics, disease severity scores), CRRT parameters (initiation timing, laboratory values), and clinical outcomes. We stratified patients by prognosis and CRRT status, and performed subgroup analyses for CRRT-treated cases. After excluding patients with definitive CRRT indications, we randomly allocated cases to training (80%) and validation (20%) sets. Using logistic regression, we identified CRRT failure predictors, evaluated their predictive value via ROC analysis, and developed/validated a nomogram prediction model.
resultsAmong 563 initially screened SAP patients, 282 were included after exclusions. (1) Prognosis analysis revealed significant differences between improved and poor outcome groups in age, pancreatitis type, CRRT use, APACHE II and Marshall scores (all P < 0.05). Multivariate analysis identified CRRT as an independent protective factor and Marshall score as a risk factor. Compared to non-CRRT patients, CRRT-treated patients showed significantly shorter hospitalization and vasopressor duration (P < 0.05), with comparable costs. (2) In CRRT-treated patients (with/without absolute indications), earlier CRRT initiation (< 36 h) correlated with better outcomes (P < 0.05). Multivariate analysis confirmed CRRT initiation time as an independent prognostic factor (optimal cutoff: 36 h). (3) Among 114 CRRT-treated patients without absolute indications (91 in training set), significant differences existed in pancreatitis type, APACHE II, Marshall score, lactate, calcium, albumin, PT and PCT (P < 0.05). Multivariate analysis identified APACHE II, PCT and lactate as independent risk factors, and calcium/albumin as protective factors for CRRT failure. The combined model showed excellent predictive value (AUC = 0.912, 95%CI:0.841-0.982). The nomogram demonstrated good calibration in both training and test sets.
conclusionsCRRT serves as an independent protective factor against poor outcomes (discharge against medical advice (death within 24 h post-discharge (against medical advice)) /death) in SAP patients, while simultaneously reducing hospitalization duration and vasopressor requirements without increasing financial burden. Early application (within 36 h) demonstrates greater therapeutic benefit. The developed nomogram prediction model, incorporating key prognostic factors, exhibits excellent clinical applicability and provides an objective basis for evaluating treatment timing in patients without strong CRRT indications.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.